Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05462639 Available - Multiple Myeloma Clinical Trials

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

MAGNETISMM17
Start date: n/a
Phase:
Study type: Expanded Access

Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity. This expanded access protocol will provide access to elranatamab until it becomes commercially accessible to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.

NCT ID: NCT05346835 Available - Multiple Myeloma Clinical Trials

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.

NCT ID: NCT05164250 Available - Multiple Myeloma Clinical Trials

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Start date: n/a
Phase:
Study type: Expanded Access

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

NCT ID: NCT04771078 Available - Multiple Myeloma Clinical Trials

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Start date: n/a
Phase:
Study type: Expanded Access

This study is designed to evaluate the safety and efficacy of nonconforming idecabtagene vicleucel (ide-cel) in participants with multiple myeloma per the approved prescribing information. This is an expanded access protocol (EAP) to be conducted at Risk Evaluation and Mitigation Strategies (REMS) qualified sites approved for commercial administration of idecabtagene vicleucel and where the EAP is authorized to be conducted for use of nonconforming idecabtagene vicleucel. Non-conforming idecabtagene vicluecel is idecabtagene vicleucel that does not meet commercial release specifications but may be acceptable for use as an investigational product in the Expanded Access Protocol setting.

NCT ID: NCT03763370 Available - Multiple Myeloma Clinical Trials

Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma

NCT ID: NCT03123029 Available - Multiple Myeloma Clinical Trials

Expanded Access to Venetoclax

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

NCT ID: NCT01250808 Available - Multiple Myeloma Clinical Trials

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Start date: n/a
Phase: N/A
Study type: Expanded Access

Multiple Myeloma (MM) is the second diagnosed malignancy of hematological malignancies. The previous study pointed out that the dosage and course of Bortezomib including the dose of concomitant drugs used to treatment MM patients did not get the preferred treatment program, so we are going to determine the optimal doses and course of Bortezomib through the prospective, multicenter clinical trial and evaluate the efficiency and safety of different program.